Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.84 -2.3%	$0.68	$0.38 ▼ $269.28	$9.50M	0.71	1.04 million shs	88,476 shs
ALZN Alzamend Neuro	$3.20 +4.9%	$3.61	$2.75 ▼ $135.54	$2.56M	-0.31	469,161 shs	448,487 shs
DWTX Dogwood Therapeutics	$4.76 -4.6%	$4.98	$1.62 ▼ $29.28	$9.09M	1.8	1.47 million shs	31,506 shs
GOVX GeoVax Labs	$0.68 +1.3%	$0.93	$0.43 ▼ $11.18	$10.76M	3.36	3.26 million shs	1.97 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	0.00%	-0.71%	-7.82%	+104.88%	-99.17%
ALZN Alzamend Neuro	0.00%	+7.93%	-1.23%	-54.94%	-91.38%
DWTX Dogwood Therapeutics	0.00%	-1.24%	+2.37%	+58.67%	+475,999,900.00%
GOVX GeoVax Labs	0.00%	+40.74%	-34.40%	-36.85%	-75.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEON AEON Biopharma	2.4307 of 5 stars	3.5	2.0	0.0	1.7	1.9
ALZN Alzamend Neuro	2.8158 of 5 stars	3.5	4.0	2.2	2.5	0.0
DWTX Dogwood Therapeutics	1.8778 of 5 stars	3.5	0.0	2.7	0.0	0.6
GOVX GeoVax Labs	2.2777 of 5 stars	3.6	2.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	3.00	Buy	$360.00	42,757.14% Upside
ALZN Alzamend Neuro	3.00	Buy	$180.00	5,525.00% Upside
DWTX Dogwood Therapeutics	3.00	Buy	$10.00	110.08% Upside
GOVX GeoVax Labs	3.29	Buy	$11.10	1,542.74% Upside

Current Analyst Ratings Breakdown

Latest ALZN, AEON, DWTX, and GOVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/2/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $9.00
4/23/2025	DWTX Dogwood Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$10.00
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	($31.66) per share	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	($7.56) per share	N/A
GOVX GeoVax Labs	$3.95M	2.73	N/A	N/A	$0.48 per share	1.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	$298.12	4.67	N/A	N/A	N/A	N/A	-994.63%	8/11/2025 (Estimated)
ALZN Alzamend Neuro	-$9.95M	N/A	0.00	N/A	N/A	N/A	-497.73%	-147.21%	7/29/2025 (Estimated)
DWTX Dogwood Therapeutics	-$12.35M	-$18.04	N/A	N/A	N/A	N/A	N/A	-34.74%	8/6/2025 (Estimated)
GOVX GeoVax Labs	-$24.99M	-$3.65	N/A	N/A	N/A	-438.20%	-511.96%	-286.58%	8/5/2025 (Estimated)

Latest ALZN, AEON, DWTX, and GOVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	N/A	AEON AEON Biopharma	-$11.51	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	GOVX GeoVax Labs	-$0.41	N/A	N/A	N/A	$0.37 million	N/A
7/29/2025	N/A	ALZN Alzamend Neuro	-$2.70	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	DWTX Dogwood Therapeutics	-$0.77	-$4.21	-$3.44	-$8.45	N/A	N/A
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
ALZN Alzamend Neuro	N/A	5.44	5.44
DWTX Dogwood Therapeutics	N/A	7.43	7.43
GOVX GeoVax Labs	N/A	3.62	3.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
ALZN Alzamend Neuro	49.61%
DWTX Dogwood Therapeutics	9.05%
GOVX GeoVax Labs	6.09%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	0.86%
ALZN Alzamend Neuro	30.21%
DWTX Dogwood Therapeutics	3.90%
GOVX GeoVax Labs	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	11.31 million	74.37 million	Not Optionable
ALZN Alzamend Neuro	4	801,000	559,000	No Data
DWTX Dogwood Therapeutics	5	1.91 million	1.84 million	N/A
GOVX GeoVax Labs	10	15.93 million	15.02 million	Not Optionable

ALZN, AEON, DWTX, and GOVX Headlines

Recent News About These Companies

GeoVax Labs, Inc. (GOVX) - Yahoo Finance

July 11 at 12:49 AM | finance.yahoo.com

Roth Capital Has Strong Estimate for GeoVax Labs Q3 Earnings

July 11 at 2:45 AM | americanbankingnews.com

GeoVax Labs (NASDAQ:GOVX) Downgraded to Sell Rating by Wall Street Zen

July 6, 2025 | americanbankingnews.com

GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat

July 3, 2025 | finance.yahoo.com

GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives

July 2, 2025 | finance.yahoo.com

GOVX - Geovax Labs Inc Dividends - Morningstar

July 2, 2025 | morningstar.comM

EQS-News: GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering

July 1, 2025 | finanzen.atF

GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering

July 1, 2025 | finance.yahoo.com

GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection - Nasdaq

June 27, 2025 | nasdaq.com

GeoVax Comments on FDA Approval of Keytruda (R) in Head and Neck Cancer, Underscoring Potential for Gedeptin (R) Combination Therapy - Nasdaq

June 26, 2025 | nasdaq.com

GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection

June 25, 2025 | theglobeandmail.com

EQS-News: GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy

June 24, 2025 | finanzen.atF

GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy

June 24, 2025 | finance.yahoo.com

GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting

June 17, 2025 | finance.yahoo.com

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA

June 16, 2025 | finance.yahoo.com

GeoVax to Participate in BIO International Convention 2025

June 12, 2025 | finance.yahoo.com

GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency

June 11, 2025 | finance.yahoo.com

GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia

June 9, 2025 | finance.yahoo.com

GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing

May 29, 2025 | finance.yahoo.com

GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance

May 27, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, AEON, DWTX, and GOVX Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.84 -0.02 (-2.33%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$0.85 +0.01 (+1.43%)

As of 08:00 AM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Alzamend Neuro NASDAQ:ALZN

$3.20 +0.15 (+4.92%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$3.26 +0.05 (+1.72%)

As of 08:14 AM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Dogwood Therapeutics NASDAQ:DWTX

$4.76 -0.23 (-4.61%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$4.78 +0.02 (+0.32%)

As of 08:02 AM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

GeoVax Labs NASDAQ:GOVX

$0.68 +0.01 (+1.32%)

As of 07/11/2025 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time